Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1978 Aug;38(2):316–324. doi: 10.1038/bjc.1978.204

Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse.

D S Alberts, Y M Peng, H S Chen, R F Struck
PMCID: PMC2009716  PMID: 698048

Abstract

We have studied the quantitative pharmacokinetic differences of individual metabolites and unchanged cyclophosphamide (CPA) in control and phenobarbital-treated animals, using radiolabelled CPA together with thin-layer chromatography. On Day 0, one group was started on phenobarbital drinking water and one group stayed on regular acid water. P388 leukaemia, (10(6) cells i.p.) was administered to all mice on Day 8, and 2 days later both groups of mice were given i.p. CPA (200 mg/kg) with 14C-CPA (0.2 muCi per mouse). At 5--60 min after CPA administration, groups of 10 mice were killed and their blood collected for assay of parent compound and metabolites in plasma. Phenobarbital pretreatment reduced CPA and phosphoramide mustard CXT (concentration x time) by 66+% and 27+%, respectively. Assuming that phosphoramide mustard is both the ultimate cytotoxic form of CPA and the blood-transport form, the reduction of CPA by phenobarbital would predict a decreased therapeutic effect. The assay methods in this study will be used in the future to determine the importance of this potential drug interaction in man.

Full text

PDF
316

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., van Daalen Wetters T. The effect of phenobarbital on cyclophosphamide antitumor activity. Cancer Res. 1976 Aug;36(8):2785–2789. [PubMed] [Google Scholar]
  2. Bakke J. E., Feil V. J., Fjelstul C. E., Thacker E. J. Metabolism of cyclophosphamide by sheep. J Agric Food Chem. 1972 Mar-Apr;20(2):384–388. doi: 10.1021/jf60180a054. [DOI] [PubMed] [Google Scholar]
  3. Colvin M., Brundrett R. B., Kan M. N., Jardine I., Fenselau C. Alkylating properties of phosphoramide mustard. Cancer Res. 1976 Mar;36(3):1121–1126. [PubMed] [Google Scholar]
  4. Colvin M., Padgett C. A., Fenselau C. A biologically active metabolite of cyclophosphamide. Cancer Res. 1973 Apr;33(4):915–918. [PubMed] [Google Scholar]
  5. Connors T. A., Cox P. J., Farmer P. B., Foster A. B., Jarman M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol. 1974 Jan 1;23(1):115–129. doi: 10.1016/0006-2952(74)90318-9. [DOI] [PubMed] [Google Scholar]
  6. Cox P. J., Phillips B. J., Thomas P. The enzymatic basis of the selective action of cyclophosphamide. Cancer Res. 1975 Dec;35(12):3755–3761. [PubMed] [Google Scholar]
  7. Fenselau C., Kan M. N., Rao S. S., Myles A., Friedman O. M., Colvin M. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res. 1977 Aug;37(8 Pt 1):2538–2543. [PubMed] [Google Scholar]
  8. Field R. B., Gang M., Kline I., Venditti J. M., Waravdekar V. S. The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo. J Pharmacol Exp Ther. 1972 Feb;180(2):475–483. [PubMed] [Google Scholar]
  9. Hart L. G., Adamson R. H. Effect of microsomal enzyme modifiers on toxicity and therapeutic activity of cyclophosphamide in mice. Arch Int Pharmacodyn Ther. 1969 Aug;180(2):391–401. [PubMed] [Google Scholar]
  10. Hohorst H. J., Draeger U., Peter G., Voelcker G. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity. Cancer Treat Rep. 1976 Apr;60(4):309–315. [PubMed] [Google Scholar]
  11. Jao J. Y., Jusko W. J., Cohen J. L. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res. 1972 Dec;32(12):2761–2764. [PubMed] [Google Scholar]
  12. Jusko W. J. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci. 1971 Jun;60(6):892–895. doi: 10.1002/jps.2600600618. [DOI] [PubMed] [Google Scholar]
  13. MCPHERSON C. W. REDUCTION OF PSEUDOMONAS AERUGINOSA AND COLIFORM BACTERIA IN MOUSE DRINKING WATER FOLLOWING TREATMENT WITH HYDROCHLORIC ACID OR CHLORINE. Lab Anim Care. 1963 Oct;13:737–744. [PubMed] [Google Scholar]
  14. Reich S. D., Bachur N. R. Alterations in adriamycin efficacy by phenobarbital. Cancer Res. 1976 Oct;36(10):3803–3806. [PubMed] [Google Scholar]
  15. Sladek N. E. Evidence for an aldehyde possessing alkylating activity as the primary metabolite of cyclophosphamide. Cancer Res. 1973 Apr;33(4):651–658. [PubMed] [Google Scholar]
  16. Sladek N. E. Therapeutic efficacy of cyclophosphamide as a function of its metabolism. Cancer Res. 1972 Mar;32(3):535–542. [PubMed] [Google Scholar]
  17. Struck R. F., Kirk M. C., Mellett L. B., el Dareer S., Hill D. L. Urinary metabolites of the antitumor agent cyclophosphamide. Mol Pharmacol. 1971 Sep;7(5):519–529. [PubMed] [Google Scholar]
  18. Struck R. F., Kirk M. C., Witt M. H., Laster W. R., Jr Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom. 1975 Feb;2(1):46–52. doi: 10.1002/bms.1200020109. [DOI] [PubMed] [Google Scholar]
  19. Voelcker G., Wagner T., Hohorst H. J. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo. Cancer Treat Rep. 1976 Apr;60(4):415–422. [PubMed] [Google Scholar]
  20. Wagner T., Peter G., Voelcker G., Hohorst H. J. Characterization and quantitative estimation of activated cyclophosphamide in blood and urine. Cancer Res. 1977 Aug;37(8 Pt 1):2592–2596. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES